Biosimilar

How It Works

Biosimilars are the closest equivalent to generic drugs for biologics, but the approval pathway is more rigorous and the price discounts are typically smaller. The FDA requires analytical, animal, and clinical studies demonstrating high similarity. Biosimilar discounts range from 15% to 85% off the reference biologic's price, compared to 80-95% discounts for traditional generics. The first wave of biosimilar competition targeted Humira in 2023, and biosimilars for Stelara, Eylea, and other blockbusters are following. Europe approved biosimilars years before the U.S., providing nearly two decades of safety data confirming equivalent outcomes.

Related Terms

• Biologic Drug — A complex medication derived from living cells — including monoclonal antibodies, vaccines, and cell therapies — that treats serious conditions like cancer and autoimmune diseases.
• Interchangeable Biosimilar — A biosimilar that meets a higher FDA standard, allowing pharmacists to substitute it for the reference biologic without prescriber approval — like a generic drug swap.
• Patent Cliff — A sharp drop in a drug's revenue when its patent expires and generic competitors enter the market, often cutting prices by 80% or more.